PHP
ONCT

Parkman Healthcare Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Parkman Healthcare Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,464
Closed -$657K – 97
2021
Q4 		$657K Sell
14,464
-1,805
-11% -$121K 0.15% 81
2021
Q3 		$1.36M Sell
16,269
-4,500
-22% -$372K 0.34% 61
2021
Q2 		$1.97M Sell
20,769
-18,170
-47% -$2.16M 0.43% 57
2021
Q1 		$6.48M Buy
38,939
+20,100
+107% +$2.66M 1.5% 22
2020
Q4 		$1.85M Buy
+18,839
New +$1.19M 0.47% 60

Other funds holding ONCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parkman Healthcare Partners's ONCT Position: Q1 2022 in Review

Parkman Healthcare Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 14,464 shares — an estimated $657K sold.

Parkman Healthcare Partners first reported a position in ONCT in Q4 2020 and held it in 5 quarters. The position peaked at $6.48M in Q1 2021. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

  • Parkman Healthcare Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 14,464 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $657K.
  • Parkman Healthcare Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Parkman Healthcare Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $6.48M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.